Gene therapy receives ‘breakthrough’ status

The US Food and Drug Administration has granted ‘breakthrough therapy’ status to a gene therapy that is in Phase 3 development for patients with an inherited eye disorder that can lead to blindness. The developer is Spark Therapeutics of Philadelphia, Pennsylvania.

Go to the profile of Victoria English
Nov 17, 2014
3
0
Upvote 3 Comment

The US Food and Drug Administration has granted ‘breakthrough therapy’ status to a gene therapy that is in Phase 3 development for patients with an inherited eye disorder that can lead to blindness. The developer is Spark Therapeutics of Philadelphia, Pennsylvania.

Breakthrough designation means a developer is eligible for a faster review of its product at the FDA. It is awarded to products that promise to significantly improve the treatment of a disease compared with an existing therapy.

The Spark gene therapy is intended to correct a mutated gene that is responsible for the production of retinal pigment epithelium-specific 65 protein, an important agent for sight. Mutations of the gene can lead to the loss of protein and to Leber’s congenital amaurosis, a severe early onset degeneration of the retina.

The therapy involves delivering the RPE65 gene in an adeno-associated virus to the back of the eye. This is done through a subretinal injection.

The Phase 3 trial is being conducted at the Children’s Hospital of Philadelphia. It is expected to report in the second half of 2015.

Spark Therapeutics announced the breakthrough therapy designation on 6 November 2014.

- Victoria English

Copyright 2014 Evernow Publishing Ltd

Go to the profile of Victoria English

Victoria English

Editor, MedNous, a publication of Evernow Publishing Ltd

Co-founder and editor of Evernow Publishing Ltd. International journalist with previous full-time editorial positions at Informa Plc, Thomson Reuters, McGraw-Hill and Dow Jones Inc. Have worked as a correspondent covering finance in New York, Amsterdam, Brussels and London, and covering healthcare and the life sciences in London.

No comments yet.